Go or no go? Apellis and Heron head for the finish line
May will see US FDA decisions for Apellis, Heron and Bristol Myers Squibb, while Provention Bio is set for a panel meeting.
Amgen’s low-dose Kras curveball
The company reveals that it will test a low dose of sotorasib, a move apparently requested by the US FDA.
Astra and Sanofi’s RSV jab takes a step towards market
A pivotal win puts nirsevimab on track to be filed next year, but the reimbursement hurdle looms.
The retreat of corporate venture funding?
Many corporate-backed funds remain enthusiastic venture investors, but some might be hitting the brakes.
Valneva joins the phase 3 Covid-19 vaccine club
Meanwhile, Ocugen hopes that Covaxin's India data will be enough for US approval.
